Organogenesis Holdings Inc. provided earnings guidance for the Fiscal Year 2023. For the year, the company expects Net revenue between $454 million and $466 million, representing an increase of approximately 1% to 3% year-over-year, as compared to net revenue of $450.9 million for the year ended December 31, 2022. Net income between $3 million and $11 million and adjusted net income between $8 million and $16 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.515 USD | -3.27% | -5.81% | -38.51% |
05-13 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
05-10 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.51% | 345M | |
+45.90% | 56.65B | |
-7.18% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.24% | 26.75B | |
-21.41% | 19.03B | |
+0.92% | 12.28B | |
+23.87% | 12.26B | |
+27.24% | 12.04B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year 2023